3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Conditions
Solid Tumors
11
Mesothelioma, Malignant
8
Solid Tumor
6
Advanced Solid Tumor
6
Mesothelioma
3
Melanoma
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Advanced Solid Tumors
3
Treatment-Refractory Solid Tumors
2
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Merkel Cell
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Solid Tumour
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Select Advanced Solid Tumors
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Locally Advanced or Metastatic Solid Tumors
1
Locally Advanced Solid Tumors
1
Locally Advanced Solid Tumor
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Interventions
Granulocyte Colony-Stimulating Factor
5
Filgrastim
5
Thiotepa
3
Cyclophosphamide
3
sargramostim
2
Topotecan
2
Melphalan
2
Ifosfamide
2
Etoposide
2
Carboplatin
2
Busulfan
2
racotumomab
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
omburtamab I-131
1
entinostat
1
cixutumumab
1
atezolizumab
1
alvocidib
1
Thrombopoietin
1
Thalidomide
1
Stem Cell Transplantation
1
Sirolimus
1
Simvastatin
1
Radiotherapy, Intensity-Modulated
1
Platinum
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Mesna
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Wilms Tumor
×
atezolizumab
×
Other solid neoplasm
×
Clear all
NCT05765084
2024-05-16
Immuno-MESODEC
University Hospital, Antwerp
Phase 1/2
Recruiting
15 enrolled